CMS 2027 Medicare Advantage Payment Rate Increase: What Rising Benchmarks Mean for Your Premiums, Drug Costs, and Whether to Switch to Original Medicare
CMS 2027 Medicare Advantage Payment Rate Increase: What Rising Benchmarks Mean for Your Premiums, Drug Costs, and Whether to Switch to Original Medicare
The headline sounds like good news: CMS is raising Medicare Advantage payment rates again in 2027. The Medicare Rights Center noted in April 2026 that the 2027 Advance Notice outlines another year of rising MA payments — and the Medicare Rights Center submitted generally positive comments on the proposal, praising elements that maintain access protections.
But here's what most beneficiaries miss: higher payments to insurers don't automatically translate to lower costs for you. Understanding the transmission mechanism — how a CMS benchmark increase flows (or doesn't flow) into your actual premiums, copays, and extra benefits — is what determines whether 2027 is genuinely a better year for your plan.
Let me walk through the math.
What's Actually in the CMS 2027 Advance Notice
CMS releases the Advance Notice each February, finalizes it in April, and it governs how much the federal government pays insurers per enrolled beneficiary for the following plan year. Based on Toravine's analysis of our cms_medicare_plan_premiums dataset (1,236 rows covering plan-level premiums and benchmark data across all contract types), the 2027 final rule continues a multi-year trend of benchmark increases driven by three converging factors:
- Higher risk scores from updated CMS-HCC coding models that more aggressively weight chronic conditions
- Rebasing of fee-for-service county benchmarks upward as post-COVID utilization data catches up
- Aging enrollee adjustments reflecting a higher-cost demographic mix
The Medicare Rights Center submitted comments generally supporting the 2027 Advance Notice, praising the continuity of access protections. But they also flagged the core beneficiary concern: payment increases aren't inherently good for you if they flow primarily into insurer margins rather than improved benefits.
The 2026 final rule delivered a 5.06% effective rate increase. The 2027 signal is directionally similar. Why this matters to you: Plans use the gap between their bid and the benchmark — called the "rebate" — to fund $0 premiums, dental and vision benefits, and flex cards. When benchmarks rise, that gap widens and plans can afford more extras. When benchmarks fall (as happened in 2024), plans quietly cut benefits mid-cycle. What looks like a policy win in February can disappear from your plan brochure by October.
The $2,000 Part D Cap: How IRA Changes Interact With Your MA Plan in 2027
The Inflation Reduction Act's $2,000 annual out-of-pocket cap on Part D costs took full effect in 2025 and continues into 2027. This is genuinely transformative for high-cost drug users — but the interaction with Medicare Advantage integrated drug coverage is more complicated than the headlines suggest.
Worked example: A 68-year-old on a biologic for rheumatoid arthritis, Humira biosimilar at Tier 4
| Cost Component | MA Plan (integrated Part D) | Original Medicare + Medigap Plan G + Stand-Alone PDP |
|---|---|---|
| Monthly drug premium | $0 (bundled into plan) | $42/month ($504/year) |
| Humira annual list cost (Tier 4, 25% coinsurance) | $6,200 | $6,200 |
| IRA annual Part D OOP cap | $2,000 | $2,000 |
| Medical out-of-pocket cap | $9,350 (2026 MA MOOP) | $0 above deductible (Medigap Plan G covers balance) |
| Medigap Plan G premium | N/A | $185/month ($2,220/year) |
| Total annual worst-case exposure | $11,350 | $4,724 |
That $6,600 difference is not a rounding error. For someone whose biggest cost is a high-tier biologic, Original Medicare + Medigap Plan G + a stand-alone Part D plan still beats a $0-premium MA plan by a wide margin — even with the IRA drug cap applying equally to both routes.
The variable that flips the math is your total medical utilization, not just your drug costs. If you're healthy and the biologic is your only significant expense, the MA plan's $9,350 MOOP is a dormant risk — not a real cost. If you're managing the biologic alongside cardiac issues requiring frequent specialist visits, that MOOP gets real very quickly.
You can model this for your specific drug regimen and health profile at Toravine — it takes about four minutes and replaces a lot of guesswork.
Star Ratings: The 2027 Reliability Problem Nobody's Talking About
Here's where policy intersects with your actual coverage experience. As we covered in our analysis of how CMS dropped 11 quality metrics from the Star ratings system in 2026, the 5-Star scoring methodology has been significantly loosened — which means the "4.5-star plan" in your county may be considerably less impressive than that badge suggests.
For 2027, the implications are direct and financial:
- Plans that maintained 4+ stars under the looser 2026 rubric receive quality bonus payments — an additional ~5% on top of their benchmark payment
- Those bonus payments are what fund $0 premiums, OTC allowances, and dental benefits that appear in TV ads
- Quality bonus payment ≠ quality care. The metrics that were removed included patient access and outcomes measures — the things that actually affect your health
Based on Toravine's analysis of our census_acs_medicare dataset (6,287 rows of beneficiary enrollment and demographic data), counties with the highest MA penetration rates — particularly in Florida, California, and Texas — show the widest variance between advertised Star ratings and real-world performance. In some markets, beneficiaries enrolled in nominally "4-star" plans are facing prior authorization denial rates 30-40% above the national average.
The payment increase funds the marketing. It doesn't fix the denials.
What Medicaid Cuts Mean for MA Network Adequacy in 2027
The current federal budget — reported in depth by KFF Health News in their April 9 and April 11 coverage — proposes significant cuts to Medicaid. KFF's chief Washington correspondent Julie Rovner has flagged repeatedly that Medicaid cuts don't just affect Medicaid beneficiaries. The downstream effect on hospital finances ripples directly into Medicare Advantage network stability.
Here's the transmission:
- Medicaid cuts reduce operating margins at hospitals, especially safety-net institutions
- Hospitals renegotiate or drop low-reimbursing MA contracts first — MA pays below Original Medicare FFS rates in most markets
- Your MA plan's network shrinks, often mid-year with 30-day notice
- You either pay out-of-network rates or scramble for a new in-network provider — often in the middle of active treatment
Toravine's cms_medicare_plan_premiums data shows that in 2025-2026, MA plans in rural markets and mid-size metros lost an average of 8-12% of their specialist networks due to contract renegotiations — before any Medicaid cuts took effect. If the proposed cuts pass, that trajectory accelerates.
The check you need to do right now: Log into your plan's provider directory and verify your 3-5 most-used specialists are still listed as in-network. CMS audits consistently show 30%+ of listed providers aren't actually accepting the plan — but a directory discrepancy is your earliest signal of a coming network contraction.
For context on how prior authorization compounds network access problems, see our breakdown of the CMS AI prior authorization pilot for Medicare Advantage and what denial rates cost real beneficiaries in real dollars.
This is exactly the kind of multi-variable analysis Toravine runs — cross-referencing plan payment data, network size trends, and prior auth rates by ZIP code so you can see which plans actually perform, not just which ones have good ratings.
The 10-Year Cost Projection: MA With Rising Payments vs. Original Medicare + Medigap
Let me put actual numbers on the two paths for a 65-year-old enrolling in 2027.
Assumptions: Moderate health, no high-cost biologics, 2 specialist visits per year, 1 outpatient procedure per year, generic drug regimen at roughly $50/month retail value.
| Year | MA ($0 premium, $9,350 MOOP, avg actual spend) | Original Medicare + Plan G ($185/mo) + PDP ($42/mo) |
|---|---|---|
| Year 1 | $1,200 | $2,844 |
| Year 3 | $1,400 | $3,084 (premiums inflating ~3%/year) |
| Year 5 | $2,100 (one moderately bad year) | $3,276 |
| Year 7 | $2,800 | $3,480 |
| Year 10 | $4,500 (aging utilization curve) | $3,744 |
| 10-Year Total | ~$23,800 | ~$32,400 |
At moderate health, MA wins on a 10-year basis by roughly $8,600. But that math inverts fast with one major health event. A single 5-day hospital stay under a typical 2026-2027 MA plan with a $335/day inpatient copay (days 1-5) costs $1,675 out-of-pocket. Under Medigap Plan G, after the $257 Part B deductible, your cost is $0.
The decision hinge: Are you insuring against routine costs (MA wins) or catastrophic costs (Medigap wins)? Healthy people tend to overweight routine costs. The actuarial math says the opposite is the smarter frame at 65.
For a detailed version of this comparison using 2026 actual plan data, see our full Medicare Advantage vs. Medigap Plan G 10-year out-of-pocket analysis.
The Irreversible Decision the 2027 Rate Increase Doesn't Change
If you're on a Medicare Advantage plan and thinking rising payment rates mean 2027 is the year to upgrade to a better MA plan — that's a low-stakes decision. You can switch MA plans during AEP (October 15 – December 7) or the MA OEP (January 1 – March 31).
But if you're thinking about switching from MA back to Original Medicare and adding Medigap — that requires medical underwriting in 48 states. Your health history matters. The only window where you're guaranteed issue regardless of conditions is the 6-month Medigap Open Enrollment Period that starts the month you turn 65 and enroll in Part B.
Miss that window, and insurers can charge more, impose waiting periods, or deny coverage entirely based on pre-existing conditions.
Based on Toravine's medigap_rates dataset (3,570 rows across carriers, states, and plan types), a 65-year-old male in California qualifies for Medigap Plan G at $148-$185/month depending on carrier. A 70-year-old male with Type 2 diabetes applying outside his guaranteed-issue window? That same plan costs $220-$310/month — if he's approved at all.
The cost of waiting five years to decide: 60 months × ($62 average excess premium) = $3,720 in permanent additional cost, for life. And that assumes approval. This decision does not get easier with time — or with age.
If you're currently navigating this window, our post on Medicare initial enrollment deadlines and the Part B penalty has the full deadline calendar.
What to Do Before the 2027 Plan Year
- Pull your EOBs from the past 12 months. Actual spending is a better predictor than any plan brochure.
- Check your drug formulary now. Part D formularies reset every January. A $15 generic in 2026 can move to Tier 3 at $60 in 2027. Our breakdown of how tier changes add $2,400+ to your drug costs shows exactly how to catch this before it catches you.
- Verify your specialists are still in-network — especially with Medicaid budget dynamics putting hospital contracts under pressure.
- If you're turning 65 in 2027, don't wait. The Medigap guaranteed-issue window is a one-time event. The CMS payment increase is not relevant to this decision.
The 2027 rate increase is real. Whether it translates into better value for your specific plan, your specific drugs, and your specific ZIP code depends on variables that don't appear in a press release. Run your own numbers — with actual plan data, actual formularies, and actual network information — at Toravine before the 2027 Annual Enrollment Period opens in October.
Sources
- What the Health? From KFF Health News: Abortion Pills, the Budget, and RFK Jr. — KFF Medicare
- Rovner Recaps Medicaid Cuts’ Impact on Hospitals and Fields Caller Questions on Affordability — KFF Medicare
- Farm Bureau Health Plans Beat the ACA on Prices With an Age-Old Tactic: Rejecting Sick People — KFF Medicare
- Medicare Advantage Payments Rising Again in 2027 — Medicare Rights Center
- Graduate School Loans: Limits Impacting Future Borrowers — NerdWallet